RecruitingPhase 2NCT07161999

Study of COYA 302 for the Treatment of ALS

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Coya Therapeutics
Intervention: COYA 302(drug)
Enrollment: 120 enrolled
Eligibility: 18-80 years · All sexes
Timeline: 2025 – 2027

Study locations (24)

Barrow Neurological Institute, Phoenix, Arizona, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
California Pacific Medical Center, San Francisco, California, United States
Nova Southeastern University, Davie, Florida, United States
University of Florida Clinical and Translational Research Center, Gainesville, Florida, United States
University Of Miami, Miami, Florida, United States
University of South Florida, Tampa, Florida, United States
Emory University, Atlanta, Georgia, United States
Northwestern, Chicago, Illinois, United States
Johns Hopkins, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
Washington University, St Louis, Missouri, United States
Neurology Associates, P.C. Somnos Clinical Research, Lincoln, Nebraska, United States
Columbia University Medical Center ALS Center, New York, New York, United States
+9 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07161999 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis →

← Back to all trials